FREDERICK, Md., Oct. 24, 2013 /PRNewswire/ -- Vaccinogen, Inc., (OTC.QB: VGEN) a cancer vaccine company, today announced that noted pediatric neurosurgeon Benjamin S. Carson, M.D. and prominent oncologist Jan B. Vermorken, M.D., Ph.D. have joined the company's medical advisory board.
Drs. Carson and Vermorken complement Vaccinogen's existing medical advisory board members: John S. Macdonald, M.D., a highly recognized colorectal surgeon; Herbert C. Hoover, Jr., M.D., a leader in the field of oncologic surgery; and Michael G. Hanna, Jr., Ph.D., Vaccinogen's Chairman and Chief Executive Officer and a leader in the field of cancer immunotherapy. Together, Drs. Carson and Vermorken bring broad knowledge of the global healthcare market and clinical oncology and previous clinical experience with OncoVAX®, the Company's investigational cancer vaccine.
"I'm excited to have joined Vaccinogen's medical advisory board at a crucial period in the development of OncoVAX," said Dr. Carson, who recently retired from his long-term position as Director of Pediatric Neurosurgery at Johns Hopkins Hospital in Baltimore. "During my career, I was fortunate enough to help save and improve the lives of many patients one by one in the operating room, but as I enter this new phase of my life, I am dedicating myself to initiatives that could have a significant, broader impact at the societal level. I believe that Vaccinogen's novel approach to immunotherapy has the potential to significantly change recurrence rates and mortality in colon cancer and, eventually, many of the most pervasive malignancies affecting the global population."
Dr. Carson is lauded for major innovati
|SOURCE Vaccinogen, Inc.|
Copyright©2012 PR Newswire.
All rights reserved